80 results
Page 2 of 4
8-K
wprkp gb1j3z
5 Jun 23
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
8:32am
8-K
EX-99.1
mho2fdcgjqb4sski1qd
5 Jun 23
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
8:32am
PRE 14A
bjooslaw 20yaqfkxjt
21 Apr 23
Preliminary proxy
4:00pm
8-K
EX-99.1
e05qskkv rn42w8qwj
30 Nov 22
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
4:20pm
8-K
xyqr pmpe
30 Nov 22
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
4:20pm
8-K
EX-99.2
vfn75qom
18 Oct 22
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
8:30am
8-K
EX-99.1
jnx6w3cwhrp7a x0r
17 Mar 22
Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:36am
8-K
EX-10.1
g7suf0r
3 Mar 22
Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer
4:50pm
8-K
EX-99.2
71s3zyahty9j1vhi4ns
10 Nov 21
Synlogic Reports Third Quarter Financial Results and Provides Business Update
8:31am
424B5
ta2jy6
23 Sep 21
Prospectus supplement for primary offering
4:20pm